Body dysmorphic disorder (BDD) is a moderately common and disabling mental health condition characterised by excessive and persistent preoccupation with perceived imperfections or flaws in one's appearance that are invisible to others, as well as repetitive behaviours that go along with it (eg, mirror checking). The disorder typically manifests throughout puberty, although it is extremely underdiagnosed and frequently goes unnoticed. BDD frequently worsens and creates clear functional impairment in several domains if left untreated. This clinical review takes into account current developments in the epidemiology and categorization of BDD, including its reclassification in the new "Obsessive-Compulsive and Related Disorders" chapter of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders. The relevance of risk assessment in this population given the high rates of suicidality and improper use of aesthetic treatments, together with the use of validated screening instruments to reduce misdiagnosis, are highlighted as important assessment issues. Additionally, a summary of the most recent research on the mechanisms and causes of BDD is provided. Cognitive behavioural therapy (CBT) and antidepressants such selective serotonin reuptake inhibitors are the suggested therapies for BDD. In adult populations, CBT and medication have both been found to be effective therapies for BDD, and there is growing evidence to support their use in young individuals. Despite the fact that the majority of patients benefit from the current evidence-based treatments, a sizable number of them still have clinically significant residual symptoms. Therefore, the need to further improve and assess current interventions with the aim of enhancing treatment outcomes and expanding their accessibility is considered as one of the top priorities for future study